Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Integrated DNA Technologies Launches First Cas9 Enzyme That Drastically Reduces CRISPR Off-Target Effects Without Significant Loss Of On-Target Activity July 31, 2017 <b>GBSI</b> Biopolicy Summit 2017 Explores Newest Lab Automation, Digital Tools And Technologies Promising Improved Preclinical Research Reproducibility — October 16 In San Francisco September 6, 2017 Allecra Therapeutics New Antibiotic Shows Promise for Resistant Bacterial Infections March 25, 2018
Integrated DNA Technologies Launches First Cas9 Enzyme That Drastically Reduces CRISPR Off-Target Effects Without Significant Loss Of On-Target Activity July 31, 2017
<b>GBSI</b> Biopolicy Summit 2017 Explores Newest Lab Automation, Digital Tools And Technologies Promising Improved Preclinical Research Reproducibility — October 16 In San Francisco September 6, 2017
